top of page
News, Events and Updates
Search
Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in AD
May 14, 2014
Anavex Strengthens Scientific Advisory Board with Clinical Trial Expert
May 11, 2014
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
May 7, 2014
Anavex Encouraged by Scientific Data; Sigma-1 Receptor Agonist is Potentially Disease-Modifying
Mar 31, 2014
Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
Mar 30, 2014
Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS
Mar 26, 2014
A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in AD
Mar 25, 2014
Anavex Successfully Closes $10M Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
Mar 18, 2014
Anavex Announces $10M Private Placement of Convertible Debentures
Mar 12, 2014
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS
Mar 9, 2014
Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
Mar 4, 2014
40
41
42
43
44
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
